TY - JOUR
T1 - When Sugar Reaches the Liver :
T2 - Phenotypes of Patients with Diabetes and NAFLD
AU - Rojano-Toimil, Alba
AU - Rivera-Esteban, Jesús
AU - Manzano-Nuñez, Ramiro
AU - Bañares, Juan
AU - Martínez Selva, David
AU - Gabriel-Medina, Pablo
AU - Ferrer Costa, Roser
AU - Pericàs, Juan M
AU - Ciudin, Andreea
PY - 2022
Y1 - 2022
N2 - Type 2 diabetes mellitus (T2DM) and non-alcoholic fatty liver disease (NAFLD) have been traditionally linked to one another. Recent studies suggest that NAFLD may be increasingly common in other types of diabetes such as type 1 diabetes (T1DM) and less frequently ketone-prone and Maturity-onset Diabetes of the Young (MODY) diabetes. In this review, we address the relationship between hyperglycemia and insulin resistance and the onset and progression of NAFLD. In addition, despite the high rate of patients with T2DM and other diabetes phenotypes that can alter liver metabolism and consequently develop steatosis, fibrosis, and cirrhosis, NALFD screening is not still implemented in the daily care routine. Incorporating a clinical algorithm created around a simple, non-invasive, cost-effective model would identify high-risk patients. The principle behind managing these patients is to improve insulin resistance and hyperglycemia states with lifestyle changes, weight loss, and new drug therapies.
AB - Type 2 diabetes mellitus (T2DM) and non-alcoholic fatty liver disease (NAFLD) have been traditionally linked to one another. Recent studies suggest that NAFLD may be increasingly common in other types of diabetes such as type 1 diabetes (T1DM) and less frequently ketone-prone and Maturity-onset Diabetes of the Young (MODY) diabetes. In this review, we address the relationship between hyperglycemia and insulin resistance and the onset and progression of NAFLD. In addition, despite the high rate of patients with T2DM and other diabetes phenotypes that can alter liver metabolism and consequently develop steatosis, fibrosis, and cirrhosis, NALFD screening is not still implemented in the daily care routine. Incorporating a clinical algorithm created around a simple, non-invasive, cost-effective model would identify high-risk patients. The principle behind managing these patients is to improve insulin resistance and hyperglycemia states with lifestyle changes, weight loss, and new drug therapies.
KW - Type 2 diabetes
KW - Type 1 diabetes
KW - Ketone-prone diabetes
KW - MODY diabetes
KW - NAFLD
KW - NASH
KW - Liver fibrosis
U2 - 10.3390/jcm11123286
DO - 10.3390/jcm11123286
M3 - Article
C2 - 35743358
SN - 2077-0383
VL - 11
JO - Journal of Clinical Medicine
JF - Journal of Clinical Medicine
ER -
